Halt™ Protease and Phosphatase Inhibitor Cocktail (100X), 1 mL - Citations

Halt™ Protease and Phosphatase Inhibitor Cocktail (100X), 1 mL - Citations

View additional product information for Halt™ Protease and Phosphatase Inhibitor Cocktail (100X) - Citations (78442, 78444, 78446, 78440)

Showing 7 product Citations

Citations & References
Abstract
Deglycosylation of pathological specimens alters performance of diagnostic PDL1 antibodies.
AuthorsDressler FF,Dabadghao DS,Klapper L,Perner S,Idel C,Ribbat-Idel J
JournalVirchows Archiv : an international journal of pathology
PubMed ID35779078
Immunohistochemical (IHC) predictive quantitation of PDL1 expression is obligatory in many cancer entities with improved response to immune checkpoint inhibition in PDL1-positive subgroups. With recent demonstration of increased positivity rates after enzymatic deglycosylation in breast cancer specimens, a comparative analysis with two different antibodies and extended controls was performed in ... More
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.
AuthorsBhagwat SV,Mur C,Vandekopple M,Zhao B,Shen W,Marugán C,Capen A,Kindler L,Stephens JR,Huber L,Castanares MA,Garcia-Tapia D,Cohen JD,Bastian J,Mattioni B,Yuen E,Baker TK,Rodriguez Cruz V,Fei D,Manro JR,Pulliam N,Dowless MS,Ortiz Ruiz MJ,Yu C,Puca L,Klippel A,Bacchion F,Ismail-Khan R,Rodrik-Outmezguine V,Peng SB,Lallena MJ,Gong X,de Dios A
JournalCancer research
PubMed ID39652577
Targeting of the estrogen receptor (ER) by antiestrogens is the standard of care for patients with ER+ HER2- advanced/metastatic breast cancer. Although antiestrogens that degrade ERα (fulvestrant) or block estrogen production (aromatase inhibitors) have improved patient outcomes, clinically important challenges remain related to drug administration, limited bioavailability, lack of brain ... More
Urologic pharmacology, Part I.
Authors
JournalSeminars in urology
PubMed ID3843699
hCLCA1 and mCLCA3 are secreted non-integral membrane proteins and therefore are not ion channels.
AuthorsGibson A, Lewis AP, Affleck K, Aitken AJ, Meldrum E, Thompson N
JournalJ Biol Chem
PubMed ID15919655
'Proteins of the CLCA gene family have been proposed to mediate calcium-activated chloride currents. In this study, we used detailed bioinformatics analysis and found that no transmembrane domains are predicted in hCLCA1 or mCLCA3 (Gob-5). Further analysis suggested that they are globular proteins containing domains that are likely to be ... More
Quantitative PCR analysis of DNA, RNAs, and proteins in the same single cell.
AuthorsStåhlberg A, Thomsen C, Ruff D, Åman P
JournalClin Chem
PubMed ID23014600
The single cell represents the basic unit of all organisms. Most investigations have been performed on large cell populations, but understanding cell dynamics and heterogeneity requires single-cell analysis. Current methods for single-cell analysis generally can detect only one class of analytes. ... More
A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
AuthorsShan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, Odunsi K, Creighton CJ, Lev DC, Anderson ML
JournalClin Cancer Res
PubMed ID22535157
Uterine leiomyosarcoma (ULMS) is a poorly understood cancer with few effective treatments. This study explores the molecular events involved in ULMS with the goal of developing novel therapeutic strategies. ... More
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.
AuthorsId Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journé F
JournalBMC Cancer
PubMed ID20565769
The proto-oncogene Src is an important non-receptor protein tyrosine kinase involved in signaling pathways that control cell adhesion, growth, migration and differentiation. It negatively regulates osteoblast activity, and, as such, its inhibition is a potential means to prevent bone loss. Dasatinib is a new dual Src/Bcr-Abl tyrosine kinase inhibitor initially ... More